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Abstract 
Background and Purpose 
Often, glaucoma courses with elevated eye hydrostatic pression, which is regulated by 
endogenous melatonin. Via 1-adrenoceptor activation, phenylephrine increases cytoplasmic 
[Ca2+] that is detrimental in glaucoma. The aims of the paper were i) elucidating the role of 
melatonin receptors in humour production and intraocular pressure (IOP) maintenance and ii) 
identifying glaucoma relevant melatonin-adrenergic interactions. 
Experimental approach 
Biophysical and proximity ligation assays were performed to identify interactions in 
heterologous systems, in cell lines and in human eyes. Gs/Gi/Gq signaling was investigated in 
heterologous systems and cells producing the aqueous humour. IOP was determined in a 
mice model of glaucoma. Retinography and topically pharmacological treatment were 
performed in control and in glaucomatous mice. 
Key Results 
1-adrenergic and melatonin receptors form functional complexes in which the C-terminal tail 
of the adrenergic receptor play a relevant role. Remarkably, activation of 1-adrenoceptors in 
the complex did not lead to cytosolic Ca2+ increases, suggesting Gs instead of Gq coupling. 
The number of complexes significantly decreased in models of glaucoma and, more 
importantly, in human samples of glaucoma patients. The results led to hypothesize that 
melatonin, a hypotensive agent, plus blockade of 1-adrenergic receptors could normalize 
pressure in glaucoma. Remarkably, co-instillation of melatonin and prazosin, an 1-adrenergic 
receptor antagonist, resulted in long-term decreases in IOP in a well-established animal model 
of glaucoma. 
Conclusions & Implications  
The findings are instrumental to understand the physiological function of melatonin in the eye 
and its potential to address eye pathologies by targeting melatonin receptors and their 
complexes. 
Key words: 1-adrenergic, Adrenergic, Melatonin, Receptor heteromer, Glaucoma, Ciliary 
body  
Abbreviations: 
4PPDOT: cis-4-Phenyl-2-propionamidotetralin (antagonist of MT2R) 
1A-MT1Hets: 1A-MT1 receptor heteromers 
AR: Adrenoceptor 
BRET: Bioluminescence Resonance Energy Transfer 
FRET: Fluorescence Resonance Energy Transfer 
GFP2: Green fluorescence protein 2 
GP: Glaucoma patients 
IIK7: N-[2-(2-Methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide (MT2R selective 
agonist) 
IOP: Intraocular pressure 
MT1R: Melatonin MT1 receptor 
MT2R: Melatonin MT2 receptor 
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1. Introduction 
Glaucoma, a pathology characterized by visual field loss, is associated with optic nerve 
damage (Casson et al., 2012).  The main risk factors are inter alia aging, genetic conditions 
and intraocular pressure (IOP) (Quigley, 2011). Besides being the second cause of blindness 
in the World, 61 million people suffer from glaucoma and by 2020 the number may approach 
80 million (Quigley and Broman, 2006). 
Normotensive IOP in adults is approximately 16 mmHg. Ocular hypertension is diagnosed 
when the value exceeds 21 mmHg (Li et al., 2018). Persistent ocular hypertension results in 
damage of the optic disc, causing degeneration of ganglion cells. The relationship between 
ocular hypertension and glaucomatous pathology is a well-known phenomenon (Sihota et al., 
2018). However, despite the current therapeutic arsenal to decrease IOP, ocular hypertension 
is still the most important risk factor for optic nerve degeneration (Rossetti et al., 2015; Tamm 
et al., 2015). 
In the healthy eye, the control of aqueous humour production is tightly controlled by 
hormones/neuromodulators, and aging leads to imbalance and increased hydrostatic pressure 
(Delamere, 2005). The role of adrenoceptors expressed in the ciliary body seems to be 
opposite as either -adrenergic agonists or ß-adrenergic antagonists may decrease IOP 
(Mittag et al., 1985; Kiuchi et al., 1992; Naito et al., 2001). Studies in different animal models 
indicated that epinephrine, i.e. the endogenous agonist, produces a reduction in IOP, which 
can be blocked by prazosin, a selective 1-adrenoceptor antagonist (Lee, 1958; Funk et al., 
1992; Moroi et al., 2000). Both epinephrine and prazosin bind the adrenergic receptor 1, a G-
protein-coupled receptor (GPCR) whose cognate heterotrimeric protein is  Gq (Alexander et 
al., 2017, 2019). 
Anti-glaucomatous compounds reduce aqueous humour formation by the ciliary body thus 
leading to a decrease in hydrostatic pressure. To combat elevated IOP, 
parasympathomimetics, adrenergic receptor antagonists, carbonic anhydrase inhibitors 
and/or prostaglandins are prescribed (Lee and Higginbotham, 2005; Hommer, 2010), although 
they may present notorious side effects (Beckers et al., 2008). Better and safer interventions 
include drug co-administration as a way to reduce doses and side effects (Polo et al., 2001). 
Interest in melatonin is emerging in ocular diseases as it modulates aqueous humour 
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hypertension likely by acting via specific receptors, MT1 and MT2 (Mediero et al., 2009; Crooke 
et al., 2012) that also belong to the superfamily of GPCRs and whose cognate protein is Gi 
(Alexander et al., 2017, 2019). Accordingly,  activation of MT1 and MT2 receptors engage Gi 
that in turn inhibits adenylyl cyclase and leads to decreasing cAMP levels and deactivation of 
protein kinase A (PKA) (Vanecek, 1998). Interestingly, melatonin receptors were reported to 
couple to different heterotrimeric G proteins and even a third melatonin receptor was 
conjectured. The exact reasons for pleiotropic signaling are not known, and the hypothesized 
third receptor is not a melatonin receptor but the enzyme quinone reductase 2  (Tsitn et al., 
1996; Pintor et al., 2001; Mailliet et al., 2004; Shiu et al., 2010; Emet et al., 2016). 
It is known that GPCRs form dimers/oligomers whose functionality is different from of that of 
individual receptors. One of the most relevant discoveries related to GPCR heteromerization 
is their ability to couple to more than one G protein and/or a shift in G-protein-coupling  (Franco 
et al., 2018). The first report on G protein coupling shift was probably that reported for 
dopamine D1/D2 receptors heteromers; whereas D1 couples to Gs and D2 to Gi, the heteromer 
couples to Gq (Rashid et al., 2007; Hasbi et al., 2009; Verma et al., 2010). Heteromers may 
consist of receptors for the same endogenous ligand or of receptors for different endogenous 
ligands. Heteromerization of the two melatonin receptors was already reported in 2013 as a 
mechanism to control photoreceptor function (Baba et al., 2013). The aims of this paper were 
i) to assess whether adrenergic receptors, which are important in the control of IOP, may form 
heteromers with melatonin receptors and ii) decipher whether those heteromers may be 
involved in the interplay between melatonin and epinephrine on IOP effects in both the healthy 
and the glaucomatous eye. 
 
2. Material and methods 
To the best of our knowledge this manuscript adheres to BJP instructions to authors and to 
the guidelines elsewhere detailed ((Curtis et al., 2018)). Studies were designed to generate 
groups of equal size, using randomization and blinded analysis. Immunological based assays 
were conducted in line with BJP guidelines detailed in (Alexander et al., 2018). 
 
2.1 Reagents 
The MT1 receptor antagonist luzindole and the MT2 receptor agonist N-[2-(2-methoxy-6H-
isoindolo[2,1-a]indol-11-yl)ethyl]butanamide (IIK7) were purchased from SigmaAldrich (St 
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hydrochloride, the MT1 receptor agonist melatonin, the MT2 receptor antagonist, cis-4-
Phenyl-2-propionamidotetralin (4PPDOT), and forskolin were purchased from Tocris 
Bioscience (Bristol, UK). 
 
2.2 Human eye postmortem samples 
Three eyes of healthy eye normotensive subjects and two of glaucoma patients (GP) came 
from donations managed by the Balearic Islands tissue bank Foundation. After fixation with 
4% paraformaldehyde, frontal sections (10 µm thick following the sagittal axis) were collected 
and stored at -20º until use. 
 
2.3 Animals and intraocular pressure measurements 
Experiments of IOP measurements were performed using female C57BL/6J 
[RRID:IMSR_JAX:000664] n=12) (control) and DBA/2J [RRID:IMSR_JAX:000671] (n=12) 
(glaucoma model) mice of different ages delivered by Charles River Lab. Institutional and 
regional Ethic Committees approved all procedures that included ARVO Statement for 
Ophthalmic and Vision Research and all experiments took into account ARRIVE guidelines. 
Mice were anesthetized by inhalation of isoflurane and IOP determined as previously 
described (Martínez-Águila et al., 2016). 
 
2.4 Cells, fusion proteins and expression vectors  
The human non-pigmented ciliary epithelial cell line, 59HCE, was kindly supplied by Dr. Coca-
Prados (Yale University) and grown in 5% heat-inactivated fetal calf bovine serum (FBS) high-
glucose Dulbecco’s-modified Eagle’s medium (Gibco/Invitrogen, Carlsbad, CA). HEK-293T 
cells [RRID:CVCL_0063] were grown in 5% FBS-DMEM (Gibco/Invitrogen, Carlsbad, CA) as 
previously described (Martínez-Pinilla et al., 2017; Navarro et al., 2018). 
The human cDNAs for the MT1, MT2 and α1A receptors (full-length or lacking its C-terminal 
domain) cloned in pcDNA3.1 were amplified without their stop codons using sense and 
antisense primers harboring either unique Hind III and BamH1 sites for MT1 and MT2 receptors 
or EcoRI and BamHI sites for α1A receptor. The fragments were then subcloned to be in frame 
with a (pRLuc-N1; PerkinElmer, Wellesley, MA), (pEYFP-N1; Clontech, Heidelberg, Germany) 
or (pGFP2-N3; Clontech, Heidelberg, Germany) placed on the C-terminal end of the receptor 
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2.5 Transient transfection and sample preparation  
Cells were transiently transfected with the cDNA encoding for each protein/fusion proteins and 
the PEI (PolyEthylenImine, SigmaAldrich, St. Louis, MO, USA) method as previously 
described (Navarro et al., 2018). Cells were incubated for 4h with the corresponding cDNA 
mixed with polyethyleneimine (PEI, 5.47 mM in nitrogen residues) and 150 mM NaCl in serum-
free medium. Finally, medium was exchanged by supplemented DMEM medium and 
maintained for 48 h in a humid atmosphere of 5% CO2 at 37ºC. 
 
2.6 FRET assays 
HEK-293T cells were transiently co-transfected with the plasmid cDNA corresponding to 
1AGFP2 or 1AmutGFP2 (donor) and MT1YFP, MT1mutYFP, MT2YFP or MT2mutYFP (acceptor) 
proteins using a ratio of donor to acceptor specified in figure legends. Cell suspension (20 µg 
of protein) was distributed into 96-well microplates (black plates with a transparent bottom) 
and was read in a Fluostar Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany) 
equipped with a high-energy xenon flash lamp, using a 10 nm bandwidth excitation filter at 
400 nm (393–403 nm), and 10 nm bandwidth emission filters corresponding to 506–515 nm 
filter (Ch 1), 527–536 nm filter (Ch 2). Gain settings were identical for all experiments to keep 
the relative contribution of the fluorophores to the detection channels constant for spectral un-
mixing. The contribution of the GFP variants, GFP2 and YFP proteins alone, to the two 
detection channels (spectral signature), was measured in experiments with cells expressing 
only one of these proteins and normalized to the sum of the signal obtained in the two detection 
channels. FRET quantification was performed as described elsewhere (Navarro et al., 2010). 
 
2.7 Intracellular Calcium Release 
Cells were co-transfected with the cDNA for the indicated receptors and 1 μg of GCaMP6 
calcium sensor (Chen et al., 2013) using the PEI method. 24h after transfection, cells were 
suspended in Mg+2-free Locke’s buffer (pH 7.4) (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO3, 
2.3 mM CaCl2, 5.6 mM glucose and 5 mM HEPES) supplemented with 10 μM glycine. 150,000 
cells/well were placed in 96-well black, clear-bottom microtiter plates, treated with receptor 
antagonists (10 min), and subsequently treated with receptor agonists. The fluorescence 
emission intensity of GCaMP6 was recorded 1 min after agonists addition at 515 nm upon 













This article is protected by copyright. All rights reserved. 
2.8 cAMP determinations 
Two hours before initiating the experiment, transfected HEK-293T cells or 59HCE cells 
medium was replaced by serum-starved DMEM medium. Then, cells were detached and 
resuspended in growing medium containing 50 µM zardaverine. Cells were plated in 384-well 
microplates (2,500 cells/well), pretreated (15 min) with the corresponding antagonists -or 
vehicle- and stimulated with agonists (15 min) before adding 0.5 μM forskolin or vehicle (15 
min). Readings were performed after 1 h incubation at 25ºC. Homogeneous time-resolved 
fluorescence energy transfer (HTRF) measures were performed using the Lance Ultra cAMP 
kit (PerkinElmer, Waltham, MA, USA). Fluorescence at 665 nm was analyzed on a PHERAstar 
Flagship microplate reader equipped with an HTRF optical module (BMG Lab technologies, 
Offenburg, Germany).  
 
2.9 Dynamic mass redistribution (DMR) assays 
Cell mass redistribution induced upon receptor activation was detected by illuminating with 
polychromatic light the underside of a biosensor and measuring the changes in the wavelength 
of the reflected monochromatic light that is a sensitive function of the index of refraction. The 
magnitude of this wavelength shift (in picometers) is directly proportional to the amount of 
DMR. Transfected HEK-293T cells or human 59HCE cells were seeded in 384-well sensor 
microplates to obtain 70-80% confluent monolayers constituted by approximately 10,000 cells 
per well. Previous to the assay, cells were washed twice with assay buffer (HBSS with 20 mM 
HEPES, pH 7.15) and incubated (2 h) with assay-buffer containing 0.1% DMSO (24°C, 30 
μl/well). Hereafter, the sensor plate was scanned and a baseline optical signature was 
recorded for 10 min before adding 10 μl of the specific antagonists for 30 min followed by the 
addition of 10 μl of specific agonists; all test compounds were dissolved in assay buffer. Then, 
DMR responses were monitored for at least 5,000 s in an EnSpire® Multimode Plate Reader 
(PerkinElmer, Waltham, MA, USA). Results were analyzed using EnSpire workstation 
Software v 4.10. 
 
2.10 β-arrestin 2 recruitment assay 
β-arrestin recruitment was determined as previously described (Hinz et al., 2018; Navarro et 
al., 2018). Briefly, BRET experiments were performed in transfected HEK-293T cells 48h after 
transfection with the cDNA corresponding to the indicated receptors fused to the YFP protein 
and 1 μg cDNA corresponding to β-arrestin 2Rluc. 48 h after transfection cells were adjusted 
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albumin for standardization. To quantify protein-YFP expression, fluorescence was read in a 
Mithras LB 940 multimode microplate reader (Berthold Technologies, Bad Wilbad, Germany) 
which allows the integration of the signals detected in the short-wavelength filter at 485 nm 
and the long-wavelength filter at 530 nm. Cells were distributed in 96-well microplates (Corning 
3600, white plates with white bottom, SigmaAldrich) BRET readings corresponding to energy 
transfer between β-arrestin 2Rluc and receptor-YFP were collected 1 min after addition of 5 
µM coelenterazine h (Molecular Probes, Eugene, OR). To quantify protein-Rluc expression, 
luminescence readings were done 10 min after 5 µM coelenterazine h addition. Net BRET is 
defined as [(long-wavelength emission)/(short-wavelength emission)]-Cf, where Cf 
corresponds to [(long-wavelength emission)/(short-wavelength emission)] for the donor 
construct expressed alone in the same experiment. BRET is expressed as milli BRET, mBU 
(net BRET x 1,000) units.  
 
2.11 Immunofluorescence and in situ proximity ligation (PLA) assays  
Frozen eye sections from healthy and glaucoma subjects were rinsed in phosphate buffer 
saline (PBS) 1X and permeabilized with PBS-0.05% Tx-100 solution for 30 min. After blocking, 
antibodies raised against MT1 (1:200, Santa Cruz, Dallas, US. Cat# sc-13179) [RRID: 
AB_677236], MT2 (1:1,000, Antibodies-online GmbH, Aachen, Germany. Cat# ABIN122307) 
and 1-adrenergic (1:500, Abcam Cat# ab3462) [RRID: AB_2224924] receptors were used. 
The rest of the protocol was similar to that elsewhere described using ad hoc secondary 
regents. PLA allows the ex vivo detection of molecular interactions between two endogenous 
proteins. PLA probes were obtained by linkage of primary anti-MT1 or MT2 receptor antibodies 
to PLUS oligonucleotide (DUO92009, SigmaAldrich, St. Louis, USA) and the 1A-adrenergic 
antibody to MINUS oligonucleotide (DUO92010, SigmaAldrich, St. Louis, USA). Samples were 
analyzed using confocal microscope (Zeiss LSM 5, Jena, Germany) at 40X magnification. The 
rest of the protocol was performed as described elsewhere, red spots were counted in each 
of the ROIs obtained in the nuclei images and data analysis was performed using specific PLA 
software (Navarro et al., 2018). 
 
2.12 Immunocytochemistry  
HEK-293T cells seeded in coverslips were transfected with 1ARluc, MT1YFP, MT2YFP, 
1ARluc and MT1YFP or 1ARluc and MT2YFP (0.5 µg cDNA each), fixed in 4% 
paraformaldehyde for 15 min and washed twice with PBS containing 20mM glycine before 
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treated for 1 h with PBS containing 1% bovine serum albumin. HEK-293T cells were labeled 
with mouse anti-Rluc antibody (1/100; Millipore, Darmstadt, Germany) and subsequently 
treated with Cy3 anti-mouse (1/200; Jackson ImmunoResearch (red)) IgG (1 h each). Nuclei 
were stain d with Hoechst (1/100; SigmaAldrich). Samples were washed several times and 
mounted with 30% Mowiol (Calbiochem). Samples were observed in a Leica SP2 confocal 
microscope (Leica Microsystems). 
 
2.13 Data analysis 
With the exception of experiments with samples from human eyes (see 2.2), all data were 
obtained from at least five independent experiments and are expressed as the mean ± SEM. 
Two-group comparisons were made by the Student’s t test and multiple comparisons were 
analyzed by one-way ANOVA followed by Bonferronis’s post-hoc test or two-way ANOVA 
followed by Tukey’s post-hoc test. The normality of populations and homogeneity of variances 
were tested prior to ANOVA. Post-hoc tests were run only if F achieved P<0.05 and there was 
no significant variance inhomogeneity. Statistical analysis was undertaken only when each 
group size was at least n=5, n being the number of independent variables (technical replicates 
were not treated as independent variables). Unequal group sizes were due to i) different 
sources depending on the wide variety of experimental approaches, ii) need of increasing the 
n value for data reliability in some of the assays, iii) animal availability and/or iv) economy of 
resources to fulfill the 3Rs’ (Replacement, Reduction and Refinement) rule in experimentation 
with animals. Differences were considered significant when P ≤0.05. Statistical analyses were 
carried out with GraphPad Prism software version 5 (San Diego, CA, USA) 
[RRID:SCR_002798]. Outliers tests were not used; all data points (mean of replicates) were 
used for analysis. 
 
 2. 14 Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018) and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017, 2019). 
 
3 RESULTS 
3.1 Melatonin and 1A-adrenergic receptors expressed in 59HCE cells are uncoupled 
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Melatonin acts via MT1 (MT1R) and MT2 (MT2R) receptors, which control Cl- efflux from ciliary 
body epithelial cells (Huete-Toral et al., 2015). Interestingly, a 1A-adrenoceptor (1A-AR) 
antagonist, prazosin, blocks the effect of melatonin on reducing IOP (Dubocovich, 1995; Pintor 
et al., 2003; Huete-Toral et al., 2015). Hence we hypothesized that melatonin and 1A-
adrenergic receptors (1AAR) could interact. 
Cognate heterotrimeric G proteins are Gi for melatonin receptors, and Gq/11 for 1A-AR 
(www.guidetopharmacology.org) (Alexander et al., 2017, 2019). However, it has also been 
reported that 1A-AR may couple to Gs (Martin, RM et al., 2018). We then measured, in 59HCE 
ciliary body epithelial cells, cAMP levels and dynamic mass redistribution (DMR) upon receptor 
activation. The effect of MT1 or MT2 receptor agonists (melatonin and IIK7, respectively) did 
not result in any decrease in forskolin-induced cytosolic [cAMP] (Fig. 1A-B). By contrast, MT1 
and MT2 receptor agonists induced a significant increase in forskolin-induced cytosolic [cAMP] 
(Fig 1A-B). When cells were challenged with the 1AAR agonist, phenylephrine, also a 
remarkable elevation of forskolin-induced cytosolic [cAMP] was achieved. The adrenoceptor-
mediated increase in cAMP reflects a Gs coupling able to overcome the forskolin-induced 
cAMP levels. The effect was specific as the antagonist, prazosin, abolished it. We also 
investigated the canonical coupling of 1AAR to Gq but failing to find any effect on Ca2+ levels 
in 59HCE cells treated with phenylephrine (Fig. 1C). These results demonstrate that human 
ciliary epithelial cells express melatonin MT1 and MT2, and 1A-adrenergic receptors that are 
not functionally coupled to their cognate G proteins. It should be noted that the concentration 
of forskolin chosen for the assays (500 nM) is submaximal thus allowing detection of either Gi- 
or Gs-coupling. Also, when MT1 and MT2 agonists were analyzed in 59HCE cells in the 
absence of forskolin, a significant increase in [cAMP] (over the basal level) was obtained (data 
not shown). 
To confirm atypical G protein coupling, similar assays were performed in the presence of 
cholera toxin (CTX), which alters Gs-mediated signaling or pertussis toxin (PTX), which alters 
Gi-mediated signaling. Results show that cholera but not pertussis toxin inhibited the action of 
agonists, unequivocally indicating Gs involvement (Fig. 1D, 1E). Neither cholera nor pertussis 
toxins by themselves produced any effect (data not shown). Interestingly, the presence of the 
1A-adrenergic antagonist, prazosin, abolished the effect of melatonergic agonists (melatonin 
on MT1R and IIK7 on MT2R). Reciprocally, the MT1R antagonist, luzindole, and the selective 
MT2R antagonist, 4PPDOT, blocked 1A-adrenergic-mediated signaling. Cross-antagonism, 
i.e. the agonist of one receptor in the heteromer is blocked by the antagonist of the partner 
receptor in the same complex, is an accepted heteromer print (Franco et al., 2016). Further 
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detecting cell dynamic mass redistribution (DMR). Apart from the cross-antagonism, the signal 
induced by any agonist was relatively high, and the combination of phenylephrine and either 
a MT1R agonist, melatonin (Fig. 1F), or a MT2R selective agonist, IIK7 (Fig. 1G), provided a 
more robust DMR response. When the experiments were carried out in the presence of 
cholera and pertussis toxins, responses were only abolished by cholera toxin (Fig. 1H-I). 
Taken together, these results suggest that the crosstalk between melatonergic and 1A-
adrenergic receptors are solely due to direct interactions and Gs coupling of resulting 
complexes. 
 
3.2 Atypical signaling in ciliary cells is due to 1A-adrenergic/melatonin receptor 
complexes. Biophysical and signaling assays in a heterologous expression system. 
To identify potential direct interactions, a FRET biophysical approach was used in HEK-293 
cells (Fig. 2A). A saturable FRET curve was obtained in cells transfected with a constant 
[cDNA] for 1A-GFP2 and increasing [cDNA] for MT1R-YFP (FRETmax 49 mFU and FRET50 44) 
(Fig. 2B). Similar experiments using increasing amounts of [cDNA] of MT2R-YFP also provided 
a saturable FRET curve with FRETmax and FRET50 values of, respectively, 168 mFU and 128 
(Fig. 2C). Thus, both melatonin receptors may form heteromers with 1AAR (1A-MT1Hets and 
1A-MT2Hets). Receptor expression and function at the plasma membrane level and 
colocalization between 1A and melatonin receptors was confirmed by immunocytochemistry 
(Supplementary Fig. S1).  
To know how heteromer formation is affecting signal transduction evens, functionality was first 
addressed in single-transfected HEK-293T cells. Upon 1AAR activation a robust increase in 
cytosolic [Ca2+] detected by the fluorescence due to calcium-bound to an engineered GCaMP6 
calmodulin sensor was obtained (Fig. 2D). The agonist effect was inhibited by prazosin, but 
not by the melatonin receptor antagonists, luzindole or 4PPDOT. In single-transfected cells, 
either MT1 or MT2 receptors were not coupled to Gq/11 (Fig. 2E-F) but to Gi, as their activation 
led to decreases in forskolin-induced cAMP levels (Fig. 2H-I). The results show that, indeed, 
when expressed individually, receptors couple to their cognate G proteins. However, 1AAR 
activation induced a significant decrease in forskolin-induced cAMP levels. This result 
demonstrates that 1AAR can couple both Gq/11 and Gi proteins when individually expressed 
in a heterologous system (Fig. 2G). Activation of receptors in single transfected cells also 
provided significant DMR read-outs (Fig. 2J-L). Finally, BRET assays performed using β-
arrestin-2-Rluc and receptors fused to YFP showed recruitment to either 1A, MT1 or MT2 
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Remarkably, cAMP determination data in co-transfected cells were similar to the results 
obtained in 59HCE cells; agonists did not decrease forskolin-induced cAMP levels in cells 
expressing 1A-MT1Hets or 1A-MT2Hets. Also, cross-antagonism was identified in co-
transfected cells, as melatonin receptor antagonists blocked phenylephrine-induced signal 
and the 1AR antagonist prazosin completely abolished the MT1R signal and slightly 
decreased the MT2R signal (Fig. 3A-B). Oddly, there was as lack of Ca2+ responses when 
phenylephrine was added to cells expressing either 1A-MT1Hets or 1A-MT2Hets (Fig. 3C-D). 
Analogies between 59HCE and co-transfected HEK-293T cells were further found in 
experiments with toxins; the combined effect of agonists was blocked by cholera but not 
pertussis toxin (Fig. 3E-F). Also, matching results in 59HCE cells, a potentiation of the label-
free DMR signal was found upon co-activation, cholera toxin did block the effect and cross-
antagonism was detected (Fig. 3G-J). These results indicate a lack of productive coupling of 
receptor heteromers with Gq/11 or Gi. Cross-modulation was found in β-arrestin-2 recruitment 
but with a particular feature, namely both 1A-receptor activation and activation of MT1 
melatonin receptors recruited β-arrestin to the 1A-receptor, co-activation resulting in a 
stronger signal (Fig. 3K). Antagonists of the two receptors abolished recruitment induced by 
agonists (cross-antagonism was, therefore, found). Similar results were obtained in cells co-
expressing 1A-MT2 heteroreceptor complexes using ad hoc agonists/antagonists (Fig. 3L).  
 
3.3 Structural insights into the mechanism underlying the atypical signaling due to 
receptor complex formation 
Since results obtained in HEK-293T cells were virtually identical to those obtained in 59HCE 
cells, we assumed that heteromers functionally coupled to Gs occur in the 59HCE cell. Looking 
at the primary structure and membrane topological domains, we hypothesized that intracellular 
domains could be responsible of such differential G protein coupling. On the one hand, the 
area projected by a G protein on the membrane plane almost doubles that of a GPCR. On the 
other hand, the “clam-shell like” opening of the small globular domain in Gα subunits, which 
occurs in every GTP/GDP exchange, has been structurally elucidated (Chung et al., 2011; 
Westfield et al., 2011). With this information and considering the structural possibilities for G 
protein-receptor complexes described elsewhere (Cordomí et al., 2015), we noticed that the 
long C-terminal domain of the 1A-adrenoceptor could lead to steric hindrance in the context 
of a complex formed by at least 2 receptors and G proteins (Rasmussen et al., 2011). It is 
predicted that the human 1A-adrenergic receptor C-terminal domain contains 137 amino acids 
(uniprot: P35348), and that human MT1 and MT2 receptors have much shorter C-terminal ends 
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lacking most of the C terminal cytoplasmic domain were obtained. Energy transfer assays 
showed interaction of 1A-AR with truncated melatonin receptors and of truncated 1A-AR with 
melatonin receptors (Fig. 4A-D). Truncated receptors, when expressed individually, were 
functional (Fig. 4E). Data from controls performed in cells co-expressing combination of 
truncated and full-length receptors are shown in Supplementary Fig. S2A-D. Functional 
assays provided clues on the atypical signaling mediated by heteromers. Phenylephrine did 
not mobilize Ca2+ in cells co-expressing 1A-AR and any of the truncated melatonin receptors 
(Fig. 4F-G). In contrast, activation of the truncated 1A-AR in the heteromeric contexts, led to 
increases in cytosolic [Ca2+] (Fig. 4H-I). In cAMP determination assays, we observed that 
truncated melatonin receptors interacting with full-length 1A-ARs were still coupled to Gs (Fig. 
4J-K). In summary, the C-terminal tail of the 1A-AR plays a relevant role in the functionality of 
the heteroreceptor functional units. 
 
3.4 The glaucomatous eye has reduced heteroreceptor complex expression and altered 
signaling 
First of all, identification of 1A-MT1Hets and 1A-MT2Hets was achieved in healthy and 
glaucomatous conditions. The in situ proximity ligation (PLA) technique is instrumental to 
detect receptor-receptor interactions in a native system. Red clusters coming from PLA assays 
proved the occurrence of both 1A-AR/MT1R and 1A-AR/MT2R complexes in 59HCE cells. 
The analysis of the PLA labeling provided values of 65±10 dots/nucleus in the case of the 1A-
MT1Hets and 73±8 dots/nucleus in the case of the MT2/α1 heteromer. The percentage of cells 
that presented positive PLA was 56±4 for 1A-MT1Hets and 57±5 for 1A-MT2Hets (n=150). 
Does eye hypertension correlate with altered expression of melatonin-adrenoceptor 
complexes? We approached this question using cells subjected to stimulation of the transient 
receptor potential vanilloid 4 (TRPV4) channel. As previously reported (Alkozi and Pintor, 
2015; Alkozi et al., 2017b), activation of the channel mimics the ion fluxes that drive the 
increase in hydrostatic pressure that occurs in the hypertensive/glaucomatous eye. The 
application to 59HCE cells of the TRPV4 agonist, GSK1016790A, modified the PLA signal in 
a dose-dependent manner. As shown in Fig. 5A-B, the higher the concentration of 
GSK1016790A, the lower the PLA signal. Therefore, a reduction in the expression 1A-
MT1Hets or 1A-MT2Hets happens when a glaucomatous condition is reproduced in a 
preclinical model (Fig. 5C). 
Exploratory experiments on heteromer expression were performed in postmortem samples 
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these unique samples that in part reflects ethical issues, we had access to 3 control (healthy) 
and 2 glaucomatous eyes. Accordingly, statistical analysis could not be performed on the 
results that are described below. In the eye from healthy donors, the presence of melatonin 
MT1, MT2 and 1A-adrenergic receptors was confirmed by immunoreactivity across the ciliary 
body (Fig. 5D-F). A strong labeling for the MT1R was present in non-pigmented epithelial cells, 
while the labeling for the MT2R was observed in the basal membrane of the non-pigmented 
epithelium (Fig. 5D-E). Melatonin receptors were not found in the stroma. Concerning the 1A-
adrenergic receptor, a positive labeling was observed in the pigmented and non-pigmented 
epithelial cells as well as in the stroma (Fig. 5F). Similar immunohistochemical studies carried 
out in samples obtained from glaucoma patients showed altered receptor expression (Fig. 5G-
I). The expression of the 1-adrenergic receptor showed a trend to increase (Fig. 5J). In sharp 
contrast, immunoreactivity for melatonin receptors was markedly reduced, 81 ± 15 and 54 ± 
13% for, respectively, MT1 and MT2 receptors. For MT1/1A and MT2/1A receptor pairs, a 
marked PLA positive labeling was observed in control samples (Fig. 5K and 5M). Remarkably, 
when PLA was performed in samples from glaucoma patients, the reduction of heteromers 
was 88% in the case of the MT1/1A and 90 % in the case of the MT2/1A heteromers (Fig. 5L, 
5N and 5O). These results obtained in human samples match the results obtained in 59HCE 
cells treated with a TRPV4 activator to mimic a glaucoma-like condition.  
 
3.5 A novel therapeutic approach to combat glaucoma 
The above described results show that the coupling of 1A-adrenoceptors to Gq and the 
subsequent Ca2+ signaling seems detrimental and markedly contributing to intraocular 
hypertension. Accordingly, an antagonist of 1A-AR would be beneficial as a blocker of calcium 
production and of Ca2+-regulated chloride channels (Fleischhauer et al., 2001). To test the 
hypothesis we moved to a well-established murine model of glaucoma (Pérez de Lara et al., 
2014). 3-month-old DBA/2J mice have normotensive eyes and physiological levels of 
melatonin. Retinal electrophysiology parameters were undistinguishable from those in the 
control mouse (C57BL/6 background) (Fig. 6A-C), however prazosin antagonized the 
hypotensive effect of melatonin (Fig. 6D). 9-month-old mice display a full glaucoma-like 
pathology (Fig. 6A-C). At 9 months of age, and despite elevated levels of melatonin (Fig. 6B), 
the glaucomatous eye of DBA/2J mice was sensitive to the hypotensive effect of exogenously 
added melatonin, which reduced the IOP from 16.6 ± 0.6 to 11.8±0.4 mmHg. Remarkably, 
prazosin, enhanced melatonin hypotensive action (to 9.0 ± 0.5 mmHg) instead of antagonizing 
it (Fig. 6F). Indeed, it was consistently found that prazosin did revert the effect of melatonin in 
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(Supplementary Fig. S2 E-H). Moreover, the effect of prazosin lasted more than 6 hours, thus 
indicating a very appropriate therapeutic time window. These results open a new and easy-to-
implement anti-glaucoma treatment, consisting of melatonin/prazosin co-administration, with 
few expectable side effects. 
 
4. Discussion 
Current therapy of glaucoma addresses symptoms by interventions neither efficacious in all 
patients nor absent of adverse events. Prostaglandin analogues have been approved for use 
by glaucoma patients because they reduce IOP but by unknown mechanisms (Sanford, 2014; 
Weinreb et al., 2015; Lanza et al., 2018). Blockers of ß-adrenoceptors or drugs able to engage 
-adrenoceptors are in the portfolio; however, the rationale behind the hypotensive action of 
to ß-blockers and -receptor agonists is unknown. 
Melatonin has become popular and is even on-line available. Its main potential is in sleep 
induction although other properties are been suggested. Already in 1993 (Serino et al., 1993) 
described the production of melatonin in the pineal gland and in the retina by methylation of 
N-acetyl serotonin (Hardeland, 2010). Interestingly, melatonin decreases IOP but the 
significant increase in the aqueous humour of glaucoma patients is not enough to normalize 
IOP (Alarma-Estrany et al., 2007) (Alkozi et al., 2017a). A complete characterization of 
melatonin receptors has not been completed due to atypical pharmacological and non-fulfilled 
suspicions of a third receptor. As receptor heteromers display particular properties, we 
reasoned that atypical data, including pleiotropic signaling, could be due to interactions with 
other GPCRs (Ferré et al., 2009). Here we selected 1A-AR because its activation leads to 
increases in cytosolic [Ca2+] that in turn control ion fluxes in the ciliary body. From our data the 
first relevant finding is that MT1 and MT2 receptors may directly interact with the 1A-AR. 
The role of epinephrine in the physiology of the eye is known since 1970 (Drance and Ross, 
1970; Zalta et al., 1983). Interestingly, the lack of coupling of receptors for epinephrine to Gq/11 
in the ciliary body (Figure 1), both intriguing and relevant, is due to 1A-Rs forming heteromers 
with melatonin receptors. Remarkably, the glaucomatous eye expresses few functional units 
and the signaling mediated by Gq-coupled 1A-ARs negatively impacts on IOP. Our results 
predicted that the effect of melatonin would be enhanced by blockade of Gq-coupled 1A-
adrenergic receptors by prazosin. Indeed, combination of the two compounds led to normalize 
IOP in a well-established model of glaucoma and the effect was not transient but lasted for 6 
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that it is very safe and does not display the serious side effects provoked by other -adrenergic 
receptor antagonists (Brogden et al., 1977). 
Our results provide an explanation for the pleiotropic signaling attributed to melatonin 
receptors and to the reported differential coupling to G proteins depending on the experimental 
system (Tsitn et al., 1996). It should be noted that MT1 and MT2 receptor heteromers still 
couple to Gi (Ayoub et al., 2004) and, therefore, the effects that are mediated by this heteromer 
are not yet elucidated from a molecular point of view. In the interaction reported in this paper 
melatonin is not by itself increasing the concentration of intracellular calcium while the 
compound, via MT1R, is able to do mobilize Ca2+ and increase phosphatidyl inositol hydrolysis 
in intestinal smooth muscle cells (Ahmed et al., 2013) Whether this atypical seemingly direct 
Gq coupling is due to heteromerization or to an alternative mechanism is, at present, unknown. 
From a mechanistic point of view, the C-terminal domain of the 1A-adrenergic receptor is 
relevant for the interaction and for the shift of heterotrimeric G protein in the adrenergic-
melatonin heteroreceptor complexes. In fact, the lack of the C tail favours Gq coupling a while 
it likely intermingles with partner melatonin receptors to impede Gq coupling. One few 
melatonin-receptor-containing melatonin receptors, is that formed by GPR50, an orphan 
GPCR with a long C terminal domain, and AT1R. Interestingly, in such heteromer there is a 
negative cross-talk that is abolished by removing the C-.terminal end of GPR50 (Lique Levoye 
et al., 2006).Therefore it seems that melatonin receptors interacting with GPCRs with long C-
terminal domains could lead to a shift in G protein coupling. To confirm this prediction more 
experimental work is needed.  
In summary, we have discovered a trend in glaucoma consisting of the disruption of complexes 
formed by adrenergic and melatonin receptors. Such trend found in animal models of the 
disease and in samples from human eye (from glaucoma patients and age-matched controls) 
makes ineffective the huge 3.2-fold increase in the concentration of melatonin in the 
glaucomatous eye. The physiological functional unit is coupled to a Gs protein whereas the 
disassembly leads to 1A-adrenergic receptors coupled to Gq and to melatonin receptors 
coupled to Gi. Increases in calcium via Gq and decreases of cAMP via Gi establish a vicious 
circle that negatively impacts on the ion channels controlling IOP. The mechanism consisting 
of allosteric interaction and shift of G protein coupling is quite noteworthy and explains one 
early finding in the laboratory that is included in the paper, namely the lack of calcium ion 
mobilization by phenylephrine in cells expressing 1A-adrenoceptors (Fig. 1C). Together, our 
findings provide a better understanding of the ciliary body physiology, completing a preclinical 
translational research addressed to combat glaucoma. Remarkably, a therapeutic strategy 
resulting from combining melatonin, sold as a supplement and lacking collateral effects even 
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approved for the therapy of blood hypertension (Brogden et al., 1977; Mallorga et al., 1988) 
(Torvik and Madsbu, 1986; Singleton et al., 1989), could readily enter into clinical trials to 
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Figure 1. Effect of melatonin receptor agonists and of phenylephrine in human 59HCE 
cells. Panels A, B, D and E: Effect of ligands (single or combined treatment) on 0.5 µM 
forskolin-induced cAMP levels in the absence (A-B) or presence (D-E) of 10 ng/mL pertussis 
(overnight) or 100 ng/mL cholera (2 h) toxins. Data are given in percentage (100% represents 
the forskolin effect); they are the mean ± SEM (n=12, each in triplicates). One-way ANOVA 
followed by Bonferroni’s multiple comparison post-hoc test were used for statistical analysis. 
*P<0.05. Panel C: Time course of cytosolic calcium levels induced by receptor agonists or by 
GSK-1016790A, an agonist of TRPV4 channels used for positive control. Panels F-I: Effect of 
ligands (single or combined treatment) on dynamic mass redistribution (DMR) in the absence 
(F-G) or presence (H-I) of pertussis or cholera toxins. Concentrations in the assays were: 100 
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Figure 2. Dimerization of 1-adrenergic and MT1 or MT2 receptors and signaling via 
adrenergic or via melatonin receptors in single transfected HEK-293T cells. Panels A-C: 
Scheme of the FRET assays (A) and results of experiments performed in HEK-293T cells 
transfected with a fixed amount of cDNA for the 1-GFP2 fusion protein and increasing 
amounts of cDNA for either MT1-YFP (B) or MT2-YFP (C). Energy transfer data are given in 
milliFRET units (mFU). The remaining experiments were performed in HEK-293T cells 
transfected with cDNAs for either 1-adrenergic, MT1 or MT2 receptors. Panels D-F: Time 
course of cytosolic calcium levels induced by receptor agonists (single or combined treatment; 
when indicated, a preincubation with antagonists was performed). Panels G-I: Effect of 
receptor ligands (single or combined treatment) on 0.5 µM forskolin-induced cAMP levels. 
Data are given in percentage (100% represents the forskolin effect); they are the mean ± SEM 
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receptor, RO-105824, was used. One-way ANOVA followed by Bonferroni’s multiple 
comparison post-hoc test were used for statistical analysis. *P<0.05.  Panels J-L: Effect of 
ligands (single or combined treatment) on dynamic mass redistribution (DMR). Panels M-O: 
BRET-bas d measurements of the effect of receptor agonists (single or combined treatment) 
on ß-arrestin 2-Rluc recruitment to every receptor-YFP fusion protein. Data are given in 
milliBRET Units (mBU); they are the mean ± SEM (n=10, each in triplicates). One-way ANOVA 
followed by Bonferroni’s multiple comparison post-hoc test were used for statistical analysis. 
*P<0.05. Concentrations in the assays in panels D to O were: 100 nM phenylephrine, 1 µM 
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Figure 3. Signaling via adrenergic/melatonin receptor functional units in a heterologous 
expression system. Experiments were performed in HEK-293T cells transfected with cDNAs 
for full-length 1A-adrenergic and either MT1 or MT2 receptors. Panels A, B, E and F: Effect of 
ligands (single or combined treatment) on 0.5 µM forskolin-induced cAMP levels in the 
absence (A-B) or presence (E-F) of 10 ng/mL pertussis (overnight) or 100 ng/mL cholera (2 
h) toxins. Data are given in percentage (100% represents the forskolin effect); they are the 
mean ± SEM (n=12, each in triplicates). One-way ANOVA followed by Bonferroni’s multiple 
comparison post-hoc test were used for statistical analysis. *P<0.05.  Panels C-D: Lack of 
effect of receptor agonists in cytosolic calcium levels. The agonist of TRPV4 channel, GSK-
1016790A, did produce an effect (data not shown). Panels G-J: Effect of ligands (single or 
combined treatment) on dynamic mass redistribution (DMR) in the absence (G-H) or presence 
(I-J) of pertussis or cholera toxins. Panels K-L: Effect of receptor agonists (single or combined 
treatment) on ß-arrestin 2 recruitment to MT1-YFP (K) or to MT2-YFP (L). Data are given in 
mBU and are the mean ± SEM (n=10, each in triplicates). One-way ANOVA followed by 
Bonferroni’s multiple comparison post-hoc test were used for statistical analysis. *P<0.05. 
Concentrations in the assays were: 100 nM phenylephrine, 1 µM melatonin, 100 nM IIK7, 1 
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Figure 4. Dimerization of truncated versions of 1-adrenergic MT1 or MT2 receptor and 
signaling via receptor heteromers containing truncated receptors. Experiments were 
performed in HEK-293T cells expressing the receptors indicated in the heading of each of the 
images. Panels A-B: FRET assays were performed in HEK-293T cells transfected with a fixed 
amount of cDNA for full-length 1-GFP2 or the truncated 1-GFP2 fusion proteins and 
increasing amounts of cDNA for, respectively full-length MT1-YFP or truncated MT1-YFP. 
Panels C-D: FRET assays were performed in HEK-293T cells transfected with a fixed amount 
of cDNA for the truncated 1-GFP2 or 1GFP2 fusion proteins and increasing amounts of cDNA 
for, respectively MT2-YFP or truncated MT2-YFP. Energy transfer data in panels A to D, are 
given in milliFRET units (mFU). Parameters were: FRETmax =43±3 mFU; FRET50 =25±5 (A), 
FRETmax =77±9 mFU; FRET50 =85±11 (B), FRETmax =100±7 mFU; FRET50 =70±8 (C) and 
FRETmax =85±11 mFU; FRET50 =137±18 (D). Panels E, J and K: Effect of ligands (single or 
combined treatment) of 0.5 µM forskolin-induced cAMP levels in cells expressing truncated 
1-adrenergic, truncated MT1 or truncated MT2 receptors (E) and in cells co-expressing 1-
adrenergic and truncated MT1 (J) or MT2 (K) receptors. Data are given in percentage (100% 
represents the forskolin effect); they are the mean ± SEM (n=12 each in triplicates). One-way 
ANOVA followed by Bonferroni’s multiple comparison post-hoc test were used for statistical 
analysis. *P<0.05. Panels F-I: Time course of cytosolic calcium level induced by receptor 
agonists (single or combined treatment) in cells co-expressing 1-adrenergic and truncated 
MT1 (F), 1-adrenergic and truncated MT2 (G),truncated 1-adrenergic and MT1 (H) or 
truncated 1-adrenergic and MT2 (I) receptors. Concentrations in the assays were: 100 nM 
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Figure 5. Identification of functional units in human 59HCE cells and in samples from 
normotensive and hypertensive human eyes. Panels A-B: Determination by PLA of 1-
adrenergic and either MT1 (A) or MT2 (B) receptor complexes in 59HCE non-pigmented ciliary 
body epithelial cells treated with increasing concentrations of the TRPV4 agonist, 
GSK1016790A.  Panel C: Quantification of clusters for 1-adrenergic and either MT1 (blue) or 
MT2 (red) receptors. Data are the mean ± SEM (n=5). *P<0.05, using Student’s t-test. Values 
for negative control were, respectively, 5±1 and 2±1 dots/nucleus). Panels D-I. 
Immunolocalization of MT1 (D), MT2 (E) or 1-adrenergic (F) receptors in the ciliary body of 
healthy controls. Immunolocalization of MT1 (G), MT2 (H) or 1-adrenergic (I) receptors in the 
ciliary body of glaucoma patients. Quantitation (J) of results comparing patients and controls 
using fluorescence values taken in identical experimental conditions. Data, given in 
percentage (100% given to values from controls) are the mean ± SEM (n=5). Statistical 
analysis could not be performed as 3 was the number of healthy eyes and 2 the number of 
glaucomatous eyes; it should be noted that the within-groups results were similar. Panels K-
O: Determination by PLA of 1-adrenergic and either MT1 (K) of MT2 (M) receptor complexes 
in the ciliary body of age-matched IOP normotensive individuals. Determination by PLA of 1-
adrenergic and either MT1 (L) of MT2 (N) receptor complexes in the ciliary body of glaucoma 
patients. Quantitation (O) of clusters comparing data in glaucoma patients and age-matched 
controls using fluorescence values taken in identical experimental conditions. Data, given in 
percentage (100% given to values from controls) are the mean ± SEM. Statistical analysis 
could not be performed as 3 was the number of healthy eyes and 2 the number of 
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Figure 6. IOP-lowering intervention in the DBA/2J mice. Panel A: Intraocular pressure (IOP) 
values of control C57BL/6J and DBA/2J mice at 3 and 9 months of age. Data are the mean ± 
SEM (n=12). *P<0.05 (Wilcoxon’s test for paired samples). Panel B: Melatonin concentrations 
in the aqueous humour of C57BL/6J and DBA/2J mice at 3 and 9 months of age. Data are the 
mean ± SEM (n=6). *P<0.05 (Wilcoxon’s test for paired samples). Panel C: Electroretinogram 
in C57BL/6J (blue) and DBA/2J (red) mice. Positive scotopic threshold response (pSTR) 
amplitude was significantly reduced between 3 and 9 months of age (P<0.05). Panels D-E: 
Time course of the effect on IOP in 3 (D) or 9 (E) month old DBA/2J mice after the instillation 
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